Best Life Sciences Platforms and Tools Companies in Toronto, Canada
The 48 best Life Sciences Platforms and Tools companies in Toronto, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: iVexSol.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Toronto
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | iVexSol Developer of a platform for the production of vectors | $39M | 42 mo ago | Series A | Rodney Rietze Co-Founder & CEO | 2018 | — | — | — |
| 2 | Intellipharmaceutics International Specialty company developing generic controlled oral solid dosage drugs | $24M | 80 mo ago | Deadpooled | Isa Odidi Chief Executive Officer | 1998 | — | — | — |
| 3 | Covalon Develops technologies, products and services to address the needs of medical device companies and healthcare… | $20M | 82 mo ago | Public | Val DiTizio Co-Founder | 2003 | WordPressApple iCloud MailMicrosoft 365+32 | — | 3 launchs |
| 4 | Axela Platforms for multiplex nucleic acid and protein analysis | $8M | 106 mo ago | Acquired | M Cynthia Goh Founder | 2001 | — | — | — |
| 5 | DoseBiome Provider of prebiotic and probiotic products | $4M | — | Deadpooled | Ted Jin Founder & CEO | 2016 | — | — | — |
| 6 | Acorn Provider of stem cell biobanking services | $3M | 30 mo ago | Series A | Patrick Pumputis Co-Founder & CSO | 2017 | WordPressMySQLPHP+35 | — | — |
| 7 | Nanovista Developing multimodal visualization agents | $2M | 102 mo ago | Seed | Jinzi Zheng Co-Founder | 2015 | — | — | — |
| 8 | Mesosil Developer of antimicrobial materials | $2M | 26 mo ago | Seed | — | 2016 | — | 6 patents Controlled ion and metal‑oxide release systems for dental and medical therapeutics | — |
| 9 | Ranomics Database of rare genetic variants | $1M | 119 mo ago | Seed | — | 2015 | WixSentryBootstrap+17 | 7 patents Patents concentrated in chemistry & materials | — |
| 10 | D5Pharma Developer of aptamer-based therapeutics to treat cancer and inflammatory diseases | $1M | 208 mo ago | Seed | Leigh Revers CEO | 2009 | — | 5 patents Therapeutic DNA aptamers targeting CD200R1 immune checkpoint modulation | — |
| 11 | Micromensio Developer of on-chip sensors for point-of-need diagnostics solution | $780K | 59 mo ago | Seed | Enver Kilinc Co-Founder & CTO | 2017 | — | — | — |
| 12 | Neurescence Provider of miniature microscope for imaging multiple regions of the brain | $350K | 63 mo ago | Acquired | — | 2014 | — | 15 patents Compact medical optical imaging and lens‑fiber focusing connectors for diagnostic devices | — |
| 13 | Spindle Biotech Providers of tools for gene editing research | $250K | 85 mo ago | Acqui-Hired | Aaron Chung CEO | 2016 | — | 6 patents In vitro RNA synthesis reagents and methods for producing synthetic RNA molecules | — |
| 14 | Amino Provider of lab equipment for bacterial transformations and culture growth | $250K | 129 mo ago | Seed | — | 2015 | Cart FunctionalityShopifySentry+32 | — | — |
Top 12 Life Sciences Platforms and Tools companies in Toronto
#1
Seed · Toronto, Ontario · founded 2016 · 5 employees$1.6Mraised▾
Mesosil develops antimicrobial materials to prevent infection at the medical device-tissue interface. It acts as local antibacterial filler material. It utilizes antibacterial self-assembled materials. The product has applications for dental restoratives and dental implant surfaces.
- Jun 2024Seed$1.6M
- 2016Seed—
#2
Series A · Toronto, Ontario · founded 2018 · 34 employees$39Mraised▾
iVexSol is a manufacturer and developer of the vector. It offers its flagship intelligent transformative platform for developing lentiviral vector cell lines.
- Jan 2023Series A$23.8M
- Dec 2020Series A$13M
- Aug 2020Seed$250K
- Sep 2019Seed$2M
#3
Series A · Toronto, Ontario · founded 2017 · 19 employees$3.3Mraised▾
Provider of stem cell biobanking services. The services include young cell preservation, non-invasive approaches, etc. This has applications in gene therapy, stem cell therapeutics, tissue engineering, organ regeneration, etc.
- Jan 2024Series A—
- Apr 2019Seed—
- Jan 2019Seed$3.3M
- 2017Seed$30K
#4
Deadpooled · Toronto, Ontario · founded 1998 · 11 employees$24.4Mraised▾
Intellipharmaceutics International develops controlled-release drug therapies by leveraging its hypermatrix technology, a proprietary multidimensional controlled-release drug delivery platform. The company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, CVS, GIT, diabetes and pain. The Hhpermatrix family of technologies includes intelliFoam, IntelliGITransporter, intelliMatrix, intelliOsmotics, intelliPaste, intelliPellets, intelliShuttle and point of divergence drug delivery system (nPODDDS). The company's products include focalin XR, effexor XR, protonix, glucophage XR, seroquel XR, lamictal XR, keppra XR, pristiq, oleptro, coreg CR, oxyContin and lyrica
- Nov 2019Post IPO$250K
- Mar 2018Post IPO$3.3M
- Mar 2018Post IPO$1.8M
- Oct 2017Post IPO$4M
#5
Public · Toronto, Ontario · founded 2003 · 88 employees$20Mraised▾
Covalon Technologies develops technologies, products and services to address the needs of medical device companies and healthcare providers. They work with medical device manufacturers to offer their partners the experience, breadth and depth of knowledge using their patent portfolio and in-house lab facilities.
- Sep 2019Post IPO$5.5M
- Aug 2018Conventional Debt$13.7M
- Aug 2016Post IPO—
- Aug 2013Post IPO$750K
#6
Seed · Toronto, Ontario · founded 2017 · 2 employees$780Kraised▾
Developer of on-chip sensors for point-of-need diagnostics solutions. The company offers scalable micro-computers data processing and communication capabilities sensing solutions that can be used in diagnostic solutions like bacteria detection, molecular diagnostics, immunoassays among others.
- Aug 2021Seed$750K
- Feb 2019Seed$30K
#7
Acquired · Toronto, Ontario · founded 2001 · 20 employees$7.8Mraised▾
Developer of life science tools and content to simplify multiplex biomarker detection for translational research and diagnostic testing. The company's portfolio of next generation, commercial stage, multiplex tools provide enhanced analysis of proteins, DNA and RNA. Its suite of products are specifically targeted at biomarker testing and infectious disease research and designed to facilitate the transition to personalized medicine, enabling researchers to understand protein interactions and develop quantitative assays on a single platform.
#8
Deadpooled · Toronto, Ontario · founded 2016 · 9 employees$4.3Mraised▾
DoseBiome is focused on oral microbiome research that improves the microbial ecosystem in the mouth by preventing diseases such as dental caries and periodontal conditions. The company is developing pre/probiotic consumer products that selectively reduce bad bacteria while promoting healthy populations of the good.
- Series A$4.3M
#9
Seed · Toronto, Ontario · founded 2015 · 3 employees$2.3Mraised▾
Nanovista focuses on visualisation agents designed specifically to enhance the performance of image-guided interventions such as surgery, radiotherapy and drug delivery. It is developing CF800, an image-guided surgery agent (Phase 1/2).
- Feb 2018Seed$2.3M
#10
Acquired · Toronto, Ontario · founded 2014 · 10 employees$350Kraised▾
Provider of miniature microscope for imaging multiple regions of the brain. The company offers Quartet is a miniature fluorescence microscope and data collection software package optimized for neuronal calcium imaging.
- May 2021Conventional Debt$350K
- Oct 2018Grant (prize money)—
#11
Seed · Toronto, Ontario · founded 2015 · 6 employees$1.3Mraised▾
Ranomics is building a database of rare genetic variants. It uses a wet lab experimental pipeline to map all genetic variants and catalogs the functionality of each variant using data modeling and statistical analysis, which can then be accessed from a secure database. Currently, it has mapped all variants of the BRCA gene and is completing it for three more genes: TP53, CHEK2, and CDK4.
- Sep 2016Seed$1.2M
- Feb 2015Seed$100K
#12
Seed · Toronto, Ontario · founded 2009$1Mraised▾
Developer of aptamer-based therapeutics to treat cancer and inflammatory diseases. The company has developed a screening platform to identify DNA aptamers to use it as a therapeutic agent. The company's lead drug product includes PEG-CCS13 that is a PEGylated single-stranded DNA aptamer used to target PD-1/PD-L1 immune evasion axis to treat disseminated cancers. The company's other DNA aptamers include Agonistic CD200R1 DNA aptamers (used as immunosuppressants and used to treat), Anti-CEA aptamers (bind the carcinoembryonic antigen found in GI tract), and Anti-TNFα aptamers (bind to the circulatory adipokine, TNFα, responsible for the acute phase of systemic inflammation). The company also uses DNA aptamers for delivery of drugs.
- Apr 2009Seed$1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Toronto is moving
A read on the academic research around Bioinformatics in Toronto — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 166 papers.
- University of Toronto155
- Toronto General Hospital6
- Toronto Metropolitan University4
- Toronto Western Hospital2
- Toronto Public Health2
- Gene2→6
- Genome2→4
- Disease9
- Biomarker5
- Identification (biology)5
- Gut flora4
- Microbiome4
- Genome1→4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.